Collaborative research initiatives
The Cancer Immune Monitoring and Analysis Centers-Cancer Immunologic Data Commons (CIMAC-CIDC) Network was launched in 2017 through the Cancer MoonshotSM initiative supported by the NCI and collaborates with another Cancer Moonshot project, the Partnership for Accelerating Cancer Therapies (PACT). Olink has been chosen as the core assay for profiling of cytokines, chemokines, and growth factors within this project, as reported in a recent article from CIMAC-CIDC/PACT:
Chen et al (2021) Clin. Cancer Res, DOI: 10.1158/1078-0432.CCR-20-3241 – article link
You can also read more about this important initiative for cancer immunotherapy research at the CIMAC-CIDC website
Maastricht University Medical Center
An exploratory prospective study, performed in collaboration with Maastricht University Medical Center, investigated circulating biomarkers of immunogenic cell death (ICD) after radiotherapy and chemotherapy in stage III NSCLC and identified important changes in immune protein profile. The overarching goal in ongoing follow-up prospective study is to improve the therapeutic efficacy of immunotherapy in stage III NSCLC patients treated with concurrent chemotherapy and photon or proton radiotherapy and adjuvant durvalumab (anti-PD-L1). Some of this work will be presented at AACR 2021, in a presentation entitled, “Biomarkers in Radiotherapy” that will be held in the session “Advances in Diagnostics and Therapeutics Session Proton Therapy and FLASH Irradiation” on Monday, April 12, 2021.
“To exploit immunotherapy for cancer optimally, biomarkers are essential for, they will lead to a personalized selection of the best treatment during the course of the disease. Blood biomarkers are ideal in this respect as they allow repeated sampling and avoid sampling heterogeneity within the tumor and between tumor locations in the same patient as is the case with tumor biopsies.”
Dr. Dirk de Ruysscher, Professor of Respiratory Oncology, Maastricht University Medical Center, Maastro Clinic, Netherlands
The joint Olink/customer poster, “Liquid biopsy protein biomarkers to predict responses and elucidate resistance to cancer immunotherapy” by Rucevic et al was presented at the Society for Immunotherapy of Cancer (SITC) meeting in National Harbor, MD in November 2019.
You are very welcome to download and read the poster – DOWNLOAD HERE
Selected publications citing Olink in cancer immunotherapy studies
Babačić H, Lehtiö J, Pico de Coaña Y, Pernemalm M and Eriksson H. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. (2020) Journal for ImmunoTherapy of Cancer, DOI: 10.1136/jitc-2019-000204
Kasanen H, Hernberg M, Mäkelä S, Brück O, Juteau S, Kohtamäki L, Ilander M, Mustjoki S and Kreutzman A. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. (2020) Cancer Immunology, Immunotherapy, DOI: 10.1007/s00262-020-02497-9
Pedersen JG, Madsen AT, Gammelgaard, KR, et. al. Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. (2020) Cancers, DOI: /10.3390/cancers12061414
Taylor M, HugheRs A, Walton J, Coenen-Stass A, Magiera L, Mooney L, Bell S, Staniszewska A, Sandin L, Barry S, Watkins A, Carnealli L and Hardaker E. (2019) Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. Journal for Immunotherapy of Cancer, DOI: 10.1186/s40425-019-0794-7
Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini M, Wikstrom K, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner M, Hagberg H and Loskog A. (2018) A Phase I/IIa Trial Using CD19-Targeted ThirdGeneration CAR T Cells for Lymphoma and Leukemia. Clinical Cancer Research, doi: 10.1158/1078-0432.CCR-18-0426
SEE ALL CURRENT OLINK PUBLICATIONS IN IMMUNOTHERAPY>
If you would like more information about how Olink’s protein biomarker solutions could help your research in this area, please submit the simple form below.